NCT03288324View on ClinicalTrials.gov

Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

August 23, 2017

Primary Completion Date

November 1, 2022

Study Completion Date

December 1, 2023

Conditions
Cutaneous LupusSystemic Lupus Erythematosus
Interventions
DRUG

Tofacitinib

Tofacitinib 5 mg twice daily

Trial Locations (2)

44109

MetroHealth Medical Center, Cleveland

45229

Cincinnati Childrens Hospital Medical Center, Cincinnati

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT03288324 - Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus | Biotech Hunter | Biotech Hunter